Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michel ATTAL, MD
University Hospital, Toulouse
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu Bordeaux
Bordeaux, France
Not, yet, recruiting - Chu de Caen
Caen, France
Not, yet, recruiting - Chu de Dijon
Dijon, France
Not, yet, recruiting - Chu de Grenoble
Grenoble, France
Not, yet, recruiting - Chru de Lille
Lille, France
Not, yet, recruiting - Hospices Civils de Lyon
Lyon, France
Not, yet, recruiting - Institut Paoli Calmettes
Marseille, France
Not, yet, recruiting - Chru de Nancy
Nancy, France
Not, yet, recruiting - Chu de Nantes
Nantes, France
Not, yet, recruiting - Chu de Rennes
Rennes, France
Not, yet, recruiting - University Hosptial Toulouse
Toulouse, France
Recruiting - Chu de Tours
Tours, France
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2018
- Primary completion
- 31 Mar 2024
- Completion
- 31 Dec 2024
- Last update posted
- 30 Jul 2020
- Registered enrollment
- 45
- Registry id
- NCT03669445
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.